Keros Therapeutics Reports Exciting Tender Offer Results
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS) has recently unveiled the preliminary outcomes of its cash tender offer aimed at repurchasing shares of its common stock. This offer involved a buyback of up to 10,950,165 shares at a fixed price of $17.75 per share, summing up to a significant total of about $194.4 million.
Tender Offer Overview
The tender offer came to a close at 5:00 p.m. Eastern Time, following which a comprehensive tally was conducted by Computershare Trust Company, N.A., designated as the depositary for the tender offer. This preliminary count revealed a total of approximately 16,659,732 shares of Keros common stock were tendered and validated.
Moreover, about 1,186,829 shares were tendered through a guarantee process. Given that the number of shares tendered exceeded Keros' purchase target, the company plans to accept shares on a pro rata basis. It is essential to clarify that any conditional tenders will be treated as withdrawn if the conditions are not fulfilled.
Implications for Stockholders
The shares being bought back as part of this tender offer represent around 35.91% of Keros' outstanding common stock. Stockholders eagerly anticipating the finalization of this offer can expect Keros to announce the confirmed number of shares for purchase soon after completing the necessary verification process.
Payment for the accepted shares will be executed promptly in cash without interest, ensuring stockholders receive their compensation without delay. The return of any other shares tendered but not purchased will also be processed quickly following the tender offer closure.
About Keros Therapeutics
As a pioneering biopharmaceutical firm, Keros is dedicated to developing innovative therapies that target a range of disorders associated with dysfunctional signaling of the TGF-ß family of proteins. These proteins play a crucial role in regulating the growth and maintenance of various tissues, including blood, muscle, and heart tissues.
Keros Therapeutics is at the forefront of realization in this field, particularly known for its lead product candidate, KER-065, directed toward the treatment of neuromuscular diseases with a focus on Duchenne muscular dystrophy. Additionally, their advanced candidate, elritercept, targets cytopenias like anemia and thrombocytopenia in patients suffering from myelodysplastic syndrome and myelofibrosis.
Stockholder Support
For stockholders seeking clarity or having inquiries regarding the tender offer, Keros has established a line of communication through MacKenzie Partners, Inc., acting as the information agent for the tender offer. They can be reached toll-free at (800) 322-2885 or at (212) 929-5500. Stockholders may also direct their questions to Goldman Sachs & Co. LLC, the dealer manager for the tender offer, at (212) 902-8556.
Conclusion
Keros Therapeutics continues to pave the way in the biopharmaceutical landscape with its innovative approaches and strategic financial planning, including this significant tender offer. The proactive engagement with shareholders echoes their commitment to transparency and value maximization.
Frequently Asked Questions
What was the purpose of Keros' tender offer?
The tender offer aimed to repurchase up to 10,950,165 shares of Keros' common stock, providing liquidity and reflecting the company’s confidence in its future.
How many shares were tendered?
A total of approximately 16,659,732 shares of Keros common stock were validly tendered, exceeding the number the company intended to buy back.
What will happen to shares not purchased?
Any shares tendered but not purchased will be returned promptly after the offer closes.
Who can I contact for more information?
Stockholders can reach out to MacKenzie Partners, Inc. or Goldman Sachs & Co. LLC for any questions about the tender offer.
What does this tender offer signify for Keros?
This offer highlights Keros Therapeutics’ dedication to enhancing shareholder value alongside its commitment to advancing therapeutic solutions in the biopharmaceutical space.
